Douglas B. Evans, MD

Publications

• Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective.

  (Ward EP, Evans DB, Tsai S.) J Surg Oncol. 2021 May;123(6):1405-1413 PMID: 33831252 SCOPUS ID: 2-s2.0-85103999698 04/09/2021

• Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy.

  (Evans DB.) Surgery. 2021 May;169(5):1032-1033 PMID: 32868112 SCOPUS ID: 2-s2.0-85090066021 09/02/2020

• Total Neoadjuvant Therapy for Operable Pancreatic Cancer.

  (Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S.) Ann Surg Oncol. 2021 Apr;28(4):2246-2256 PMID: 33000372 SCOPUS ID: 2-s2.0-85091728559 10/02/2020

• Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer.

  (Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY.) Surgery. 2021 03;169(3):629-635 PMID: 32826069 SCOPUS ID: 2-s2.0-85089521842 08/23/2020

• An Institutional experience with primary hyperparathyroidism in the elderly over two decades.

  (O'Sullivan K, Yen TWF, Doffek K, Dream S, Mazotas I, Evans DB, Wang TS.) Am J Surg. 2021 Jan 30 PMID: 33551115 SCOPUS ID: 2-s2.0-85100630649 02/09/2021

• Tips for authors of surgical manuscripts from senior reviewers.

  (Malangoni MA, Evans DB, Prinz RA, Hodin RA, Rege R, Harken AH.) Surgery. 2021 Jan 22 PMID: 33494949 01/27/2021

• Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level.

  (Zimmermann MT, Mathison AJ, Stodola T, Evans DB, Abrudan JL, Demos W, Tschannen M, Aldakkak M, Geurts J, Lomberk G, Tsai S, Urrutia R.) Front Oncol. 2021;11:606820 PMID: 33747920 PMCID: PMC7973372 SCOPUS ID: 2-s2.0-85102941394 03/23/2021

• Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.

  (Gao C, Wisniewski L, Liu Y, Staal B, Beddows I, Plenker D, Aldakkak M, Hall J, Barnett D, Gouda MK, Allen P, Drake R, Zureikat A, Huang Y, Evans D, Singhi A, Brand RE, Tuveson DA, Tsai S, Haab BB.) Clin Cancer Res. 2021 Jan 01;27(1):226-236 PMID: 33093149 PMCID: PMC7785673 SCOPUS ID: 2-s2.0-85100339220 10/24/2020

• Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods.

  (Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S.) Am J Surg. 2020 Dec 03 PMID: 33308823 SCOPUS ID: 2-s2.0-85097458297 12/15/2020

• The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.

  (Evans DB.) Ann Surg. 2020 09 01;272(3):487 PMID: 32657915 SCOPUS ID: 2-s2.0-85099375677 07/14/2020

• Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy.

  (Kim RY, Evans DB, Christians KK.) Hepatobiliary Surg Nutr. 2020 Aug;9(4):497-500 PMID: 32832502 PMCID: PMC7423551 08/25/2020

• Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

  (Taskin OC, Clarke CN, Erkan M, Tsai S, Evans DB, Adsay V.) J Gastrointest Oncol. 2020 Jun;11(3):548-558 PMID: 32655934 PMCID: PMC7340800 SCOPUS ID: 2-s2.0-85090285071 07/14/2020